CARsgen Expands CAR-T Manufacturing Base through New Strategic Partnerships in Shanghai

CARsgen Therapeutics Holdings Limited, publicly listed under stock code 2171.HK, is advancing in the development of CAR T-cell therapies by announcing significant strategic partnerships. On February 12, 2026, the company revealed it has signed cooperation agreements via its fully-owned subsidiary, CARsgen Diagnostics, in collaboration with Shanghai Jingong Enterprise. This enterprise is a critical player in the technologically progressive Bay Area High-Tech Zone located in Jinshan District, Shanghai.

The total investment for this venture is aimed not to exceed RMB 370 million, a strategic move that involves establishing an advanced commercial manufacturing facility dedicated to CAR T-cell products in Jinshan. This facility is particularly important as it aligns with CARsgen’s plans to commercialize various CAR T-cell therapies, including their recently marketed "zevorcabtagene autoleucel" and the promising "satricabtagene autoleucel" (RD code "CT041"), currently in the New Drug Application (NDA) stage for solid tumors. Furthermore, this setup paves the way for the mass production of multiple allogeneic CAR T-cell products, such as CT0596 and CT1190B, which are crucial for the company's future pipeline.

The effort aims at enhancing CAR T-cell manufacturing standards in accordance with international guidelines, a primary goal that underscores the commercialization of several products while strengthening CARsgen's global competitive edge. Notably, this agreement allows CARsgen to preserve significant capital at this early stage, safeguarding cash flow for vital research and development endeavors, as well as market expansion strategies. Additionally, a repurchase mechanism has been integrated to ensure that CARsgen can maintain control over its assets. This stability facilitates enhanced flexibility and strategic asset positioning in the long run.

This collaboration reflects CARsgen's astute financial planning as well as an extensive preparation framework within the CAR T-cell therapy industry. The project has harmonized with national and regional biopharmaceutical initiatives, garnering considerable attention and robust support from government entities. Consequently, this strategic partnership is positioned to solidify CARsgen's dominance in the competitive CAR T-cell therapy landscape while creating sustainable value for its shareholders.

About CARsgen Therapeutics Holdings Limited

CARsgen is a pioneering biopharmaceutical firm dedicated to breaking new ground in CAR T-cell therapies to meet significant clinical needs in various fields, from hematologic malignancies and solid tumors to autoimmune diseases. The company boasts an end-to-end operational framework that encompasses everything from target discovery to preclinical studies, clinical development, and production at a commercial scale. CARsgen has not only cultivated innovative in-house technologies but has also built a product pipeline with the global rights designed to tackle the challenges traditionally linked to CAR T-cell therapies. With efforts focused on improving safety profiles, increasing treatment efficacy for solid tumors, and reducing costs, CARsgen is driven by a mission to emerge as a global leader in biopharmaceuticals, providing innovative therapies for patients worldwide and striving toward making cancer and other diseases treatable.

Forward-Looking Statements

This press release contains forward-looking statements that share the Group's current outlook, expectations, and intentions regarding future events, as of the release date. Such statements are based on a variety of assumptions and factors that are beyond the Group's influence and are subject to risk and uncertainty, which may lead to outcomes that differ materially from those anticipated. For a comprehensive overview of identified risks and uncertainties, refer to the latest annual and interim reports and other documents available through CARsgen's official website. No assurances are provided regarding the realization or viability of projections or estimates discussed herein.

For further information, please visit CARsgen's official website.